Organization
Organización Medica de Investigación
1 abstract
Abstract
BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASEOrg: AbbVie Inc., North Chicago, IL, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, Rheumatism Foundation Hospital, Heinola, National Public Health Institute, Helsinki, Finland, Centre for Immunology and Cancer Research, University of Queensland, Brisbane, Australia, Emeritus Research Melbourne, Monash University School of Public Health and Preventive Medicine, Organización Medica de Investigación,